期刊文献+

大鼠肌注伤寒Vi多糖蛋白结合疫苗的长期毒性

Long-term toxicity of intramuscularly injected typhoid conjugate vaccine in rats
下载PDF
导出
摘要 目的:观察SD大鼠肌注伤寒Vi多糖蛋白结合疫苗的长期毒性。方法:疫苗组大鼠(n=24)免疫3针,每次每只25μg(以多糖量计),第1剂免疫后2周,第3剂免疫后1,3和5周各处死6只大鼠,测血常规、血清测特异性抗体、血清生化,并进行组织器官病检。结果:疫苗组大鼠血液学白细胞分类出现可逆性的变化(P<0.05,P<0.01),但无明显毒性,血清特异性抗体阳性大鼠病理组织检查未见免疫毒理学损伤。结论:伤寒Vi结合疫苗对大鼠有明显的免疫原性,但无明显毒性和局部刺激性。 Objective: To evaluate the long-term toxicity of intramuscularly injected typhoid conjugate vaccine in Sprague-Dawley (SD) rats. Methods: Rats (n = 24) were repeatedly immunized with intramuscular typhoid conjugate vaccine at 25 μg for 3 times. Two weeks after the first immunization, 1, 3 and 5 weeks after the third immunization, 6 rats were respectively sacrificed for examination of hematology, serum biochemistry, the specific antibody against vaccine, and histopathology. Results: In rats immunized with the vaccine, reversible changes of hematology were observed, but did not show apparent toxicity. Immunotoxic damage was not found by examination of histopathology in specific antibody-positive rats, suggesting that the specific antibody would not be harmful to the rats. Conclusions: Typhoid conjugate vaccine after repeated immunization has potent immunogenicity but no observed toxicity in rats.
出处 《中国新药杂志》 CAS CSCD 北大核心 2008年第7期565-569,共5页 Chinese Journal of New Drugs
基金 863重大课题“疫苗与工程抗体”专项课题(编号:2006AA02A218) 甘肃省科技重大专项课题(编号:2GS052-A43-008-01)
关键词 伤寒Vi结合疫苗 长期毒性 免疫原性 免疫毒性 typhoid conjugate vaccine long-term toxicity immunogenicity immunotoxicity
  • 相关文献

参考文献13

  • 1LIN FY, HO VA, KHIEM HB, et al. The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children [ J]. N Engl J Med,2001,344 ( 17 ) : 1263 - 1269.
  • 2蒲江,杜琳,谭小梅,侯亚莉,蒋奕,金学敏,谢贵林.伤寒Vi-rEPA结合疫苗在小鼠中的免疫原性研究[J].微生物学免疫学进展,2004,32(4):14-17. 被引量:5
  • 3佟之复.伤寒疫苗[J].疾病监测,2001,16(4):157-159. 被引量:1
  • 4U.S. Department of Health & Human Services, FDA Office of Women's Health and CBER: Workshop on non-clinical safety evaluation of preventive vaccines: recent advances and regulatory considerations. Arlington, Virginia [ EB/OL ]. [ 2002 - 12 - 03 ]. http://www. fda. gov/cber/minutes/tox120302, htm.
  • 5EMEA:Note for guidance on preclinical pharmacological and toxicological testing of vaccines. Lonton. CPMP/SWP/d65/95 [ EB/ OL]. [ 1997 - 12 - 17 ]. http ://www. emea. europa, eu/pdfs/human/swp/046595cn, pdf.
  • 6EMEA:ICH Topic S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals. CPMP/ICH/302/95 [ EB/OL ]. [2003 -02 - 10 ]. http://www, emea. europa, eu/pdfs/human/ ich/030295 en. pdf.
  • 7U.S. Department of Health & Human Services, FDA Office of Women's Health and CDER:Guidance for industry immunotoxicology evaluation of investigational new drug. [ EB/OL ]. [ 2002 - 10]. http://www, fda. gov/Cder/guidanee/4945fnl, htm.
  • 8WHO Guidelines on Preclinical Evaluation of Vaccine (Draft). [EB/OL]. [2003 - 11 - 17]. http://www, pasteur, fr/recherche/C rvbm/Documents/WHO_Nonclinical_evaluation vaccines_ Nov__2003. pdf
  • 9VERDIER F. Non-clinical vaccine safety assessment[ J]. Toxicology,2002,174 ( 1 ) :37 - 43.
  • 10EMEA. Note for guidance on requirements for the evaluation of new adjuvants in vaccines. Lonton. CPMP/BWP/6622/03-2 [EB/OL]. [2002 -04 -25]. http://ww. emea. europa, eu/ pdfs/human/bwp/662202 en. pdf.

二级参考文献35

  • 1沈玉霖,扈晶,王秉瑞,计国欣,张河战,辜清吾.伤寒Vi荚膜多糖菌苗的研究[J].中国生物制品学杂志,1991,4(1):5-8. 被引量:3
  • 2杨进,司国爱,曾竣,张杰,梁贵臣,梁大斌,廖和壮,李翠云,黄焕新,董柏青,杨宏徽,Rion Leon Ochiai,Carolina Danovaro,Ali Mohammad,Camilo J Acosta.5~60岁人群伤寒Vi多糖疫苗和A群脑膜炎球菌多糖疫苗大规模接种结果分析[J].中国计划免疫,2004,10(4):234-237. 被引量:6
  • 3王志高,周伟忠,史鉴,王同来.伤寒Vi多糖菌苗流行病学效果观察[J].中华流行病学杂志,1997,18(1):26-29. 被引量:25
  • 4Robbins JD, Robbins JB. Re-examination of the protective role of the capsular polysaccharide(Vi antigen) of Salmonella typhi[J]. J infect Dis 1984,150:436-449.
  • 5Edelman R, LeVine MM. Summary of an international workshop on typhoid fever[J].Rev Infect Dis 1986,8:329-349.
  • 6Whiteside RE, Baker EE. The Vi antigen of the Enterbacteriacae immunologic and biologic properties[J].J Immunol 1959,83:687-696.
  • 7Szu SC, Stone AL, Robbins JD, et al. Vi capsular polysacchride-protein conjugates for prevention of typhoid fever[J].J Exper Med 1987,166:1510-1524.
  • 8Szu SC, Stone AL, Robbins JD, et al Preparation and Characterization of conjugates of the Vi capsular polysaccharide and carrier proteins[J]. J Exp Med 1987,2:1165-1169.
  • 9Kossaczka Z, Lin FY, Ho AV, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid in adult, teenagers, and 2-to-4-year-old children in Vietnam[J].Infect Immun 1999,67:5806.
  • 10Crump JA,Luby SP,Mintz ED.The global burden of typhiod fever[J].Bull WHO,2004,82(5):346-353.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部